ZENTALIS PHARMACEUTICALS INC (ZNTL)
Health Care · Clinical-stage oncology / biopharmaceuticals; WEE1 kinase inhibitors · NASDAQ
Zentalis Pharmaceuticals is a clinical-stage oncology company developing azenosertib, a potentially best-in-class WEE1 inhibitor, targeting biomarker-selected populations in ovarian cancer.
What ZENTALIS PHARMACEUTICALS INC does
Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of small molecule therapeutics for oncology. Its lead candidate, azenosertib (ZN-c3), is an investigational WEE1 inhibitor designed to treat patients with Cyclin E1-positive platinum-resistant ovarian cancer (PROC) and other solid tumor types. The company utilizes proprietary biomarker-driven strategies, specifically targeting Cyclin E1 overexpression, to identify patient populations likely to benefit from its therapies.
Themes: Oncology / ovarian cancer, WEE1 inhibitors, Cyclin E1-positive tumors, Platinum-resistant ovarian cancer (PROC), Biomarker-directed cancer therapy, DNA damage response / cell cycle control
Fundamentals
- Price$3.83 as of 2026-08-21 close
- Market cap$274M as of 2026-08-21
- 1-year return+104.5% 2025-08-21 close $1.87 → 2026-08-21 close $3.83
- P/En/a negative earnings
- Net margin-246.0% as of 2026-08-24
- ROE-52.8% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Beta1.95 as of 2026-08-24
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How ZNTL compares in its sector
- net profit marginbottom 25% 504 covered Health Care peers, as of 2026-08-24
- operating marginbottom 25% 504 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How ZENTALIS PHARMACEUTICALS INC looks technically
ZENTALIS PHARMACEUTICALS INC (ZNTL) is trading 24.0% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 150 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 19, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 41, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 6 trading days ago. It is 45.0% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 24.0% above its 200-day average, the long-term trend line — a longer-term uptrend | +24.0% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $4.33 | $4.33 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $3.09 | $3.09 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 7 calendar days ago — the swings before that are what the structure reading is measured on | 7 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that downward direction; the labelling fails if price closes above 4.131. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a completed three-part correction. | possible downward five-wave sequence, in wave 4 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 150 trading days ago — a "golden cross", a bullish long-term signal | 150 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 19, below the 25 that marks a real trend) | 18.7 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 41, neither overbought (above 70) nor oversold (below 30) | 40.6 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($3.49 to $5.15) — its "stochastic" reading is 20 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 20.2 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 11 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $6.95 | $6.95 |
|---|---|---|
| From the 52-week high | it is 45.0% below its 52-week high (its highest price of the past year) | -45.0% |
| Above the 52-week low | it is 215.6% above its 52-week low (its lowest price of the past year) | +215.6% |
| Below the 52-week high | it is 45.0% below its highest point of the past year | 45.0% |
| Since a 20-day breakout | it made a new 20-day low about 6 trading days ago | 6 sessions |
| Since a 55-day breakout | it made a new 55-day high about 26 trading days ago | 26 sessions |
| All-time high | its highest closing price on record is $86.68 (set on 2021-11-04) | $86.68 |
| Given back of the 52-week move | over the past year its closes ranged ($1.28 to $6.61), and it has given back around half of its rise from last year’s low — 52% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $3.15 to $3.32. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 52.3% |
| From the all-time high | it is 95.6% below its all-time high | -95.6% |
| Nearest price level | it is trading 3.9% below a resistance level at $3.98 — a price it turned at twice since 2024-12-09, most recently on 2026-01-12. Since 2024-08-21 it has 11 such levels below the current price and 4 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +3.9% |
| All-time low | its lowest closing price on record is $1.01 (set on 2025-04-09) | $1.01 |
| Above the all-time low | it is 278.7% above its all-time low | +278.7% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are wider than usual versus its own recent 6-month history (wider than about 76% of it) | 76th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.3422 between its high and its low — about 9.0% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.3422 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $3.39 and $5.24 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $3.39 – $4.31 – $5.24 |
| Typical daily range (% of price) | its price moves about 9.0% in a typical session — among the most volatile in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 8.9% |
| Stretch from the 200-day average | it is trading 2.2 daily ranges above its 200-day average price (24.0% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 2.2 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.58× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 6.0% since the prior reading | +6.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 2.9% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +2.9% |
|---|---|---|
| Open gap | it gapped 14.9% below the previous close 5 sessions ago and has not traded back through the level it left behind at 4.15 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -14.9% |
| Gap filled | a 2.9% gap up opened on 2026-08-21 has been "filled" today — price traded back through the level the gap left behind, and it closed again during the very session that opened it | today |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 26.0 percentage points (the stock lost 23.7% while the market gained 2.3%) | -26.0% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 10.7 percentage points (the stock lost 7.6% while the market gained 3.1%) | -10.7% |
| vs market, 6 months | over the past 6 months this stock beat the market by 47.0 percentage points (the stock gained 58.1% while the market gained 11.1%) | +47.0% |
| vs market, 12 months | over the past 12 months this stock beat the market by 84.1 percentage points (the stock gained 104.5% while the market gained 20.5%) | +84.1% |
Signal agreement
2
| Bullish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, outperforming the market over 6 months — these describe past price behaviour, not a forecast | 3 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: MACD momentum is negative, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 10% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 4.6% of the share price. | -10.3% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 10% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $4.27 — a volume-weighted average of daily closes over 155 sessions, not a true tick-by-tick VWAP. | -10.5% |
|---|---|---|
| Vs the average paid since it last reported | the price is 1% below the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is under water. That average is $3.87 — a volume-weighted average of daily closes over 12 sessions, not a true tick-by-tick VWAP. | -1.3% |
Price levels it has turned at before
ZNTL last closed at $3.83 on 2026-08-21. Since 2024-08-21 it has turned at 11 prices below its last close and 4 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $3.98 | Resistance | 3.9% above the last close | turned there twice · 2024-12-09 to 2026-01-12 |
| $3.48 | Support | 9.2% below the last close | turned there twice · 2026-05-20 to 2026-08-14 |
| $3.40 | Support | 11.1% below the last close | turned there twice · 2024-10-24 to 2026-06-05 |
| $4.32 | Resistance | 12.9% above the last close | turned there three times · 2026-04-28 to 2026-07-10 |
| $4.45 | Resistance | 16.4% above the last close | turned there twice · 2024-11-13 to 2026-05-11 |
| $2.97 | Support | 22.4% below the last close | turned there twice · 2024-08-28 to 2024-09-06 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes above $4.13.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $3.88 and $4.13 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a completed three-part correction, which fails on a close below $3.49.
This reading has stood for 1 trading day, since 2026-08-21.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Pulled back from the 12-month high · trendless / choppy (low ADX) · Analyst price target recently RAISED · beating the market · Most volatile (6%+ typical daily range) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (2.11 mean, 1=Strong Buy…5=Strong Sell) — 9 analysts
- Mean price target$6.89 range $4.00 – $10.00; median $6.00
Analyst estimates, as of 2026-08-18. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for ZNTL
- Consensus EPS estimate-$0.5771 next reporting period, as of 2026-08-18
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Clinical development risk: azenosertib is still in Phase 2/3 trials with no approved products, and failure to achieve efficacy endpoints in DENALI Part 2 or ASPENOVA trials could prevent regulatory approval and product commercialization.","Regulatory approval uncertainty: accelerated approval pathway is dependent on FDA discretion and successful trial outcomes; even if approved, the Phase 3 ASPENOVA trial must achieve confirmatory efficacy data for conversion to full approval.","Limited market size and patient population: the addressable market for Cyclin E1-positive PROC is estimated at approximately 21,500 patients annually in key markets; failure to achieve rapid adoption or discover additional indications would constrain revenue potential."]
What changed in the latest 10-Q
AI-assisted comparison of ZNTL's 10-Q filed 2026-05-12 against the prior one filed 2025-11-10.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing references 'Annual Report on Form 10-K for the year ended December 31, 2025' (vs. 2024 in older filing)
- Newer filing states azenosertib is for 'other tumor types' rather than 'across other solid tumor types'
- Newer filing adds reference to 'Our Phase 3 ASPENOVA clinical trial is designed as a confirmatory trial to support conversion to potential full approval'
- Newer filing adds 'real-world data from two independent cohorts (Tempus Lens Ovarian cancer dataset and our historical clinical studies) presented at the 2026 American Association for Cancer Research, or AACR, annual meeting' to biomarker discussion
- Newer filing adds 'retrospective' to market opportunity analysis ('Based on our retrospective, historical analysis')
- Newer filing specifies market opportunity narrative includes 'The limited overlap between FRα-high PROC patients and those that have Cyclin E1 overexpression is estimated to be less than 20% of all PROC patients'
- Newer filing adds specific details on DENALI Part 2a dose selection: 'In April 2026, we announced that 400mg QD 5:2 was selected as the pivotal monotherapy dose and that recruitment at the 300mg QD 5:2 dose level has been discontinued'
- Newer filing adds DENALI Part 2c cohort description: 'Broadening study population, which is expected to include approximately 40 patients previously treated with a taxane-containing regimen for PROC'
- Newer filing adds 'The FDA has granted Fast Track Designation to azenosertib for the treatment of patients with Cyclin E1-positive PROC' (with more specific language than older filing)
- Removed:
- Older filing's reference to 'as a combination therapy' in market opportunity section is removed in newer filing
- Older filing's specific reference to 'mirvetuximab soravtansine' is shortened to 'mirvetuximab' in newer filing
- Older filing's detailed DENALI Part 1b description mentioning 'In January and March of 2025, we announced clinical data' is condensed to 'In 2025, we announced clinical data' in newer filing
- Older filing's description of DENALI Part 2 original design (approximately 100 patients, specific prior lines of therapy language) is replaced with more detailed three-cohort structure in newer filing
- Older filing's reference to 'April 2025' announcement of first patient dosed in DENALI Part 2a is removed from newer filing
- Older filing's statement 'We plan to conduct a randomized, controlled Phase 3 confirmatory clinical trial' is replaced with more specific 'ASPENOVA – ZN-c3-020' details in newer filing
- Older filing's entire section on 'Monotherapy – Phase 2 Clinical Trial in Uterine Serous Carcinoma, or USC (TETON - ZN-c3-004)' is not present in newer filing excerpt
- Reworded:
- Older: 'has potential to support an application seeking accelerated approval' changed to newer: 'has the potential to support an accelerated approval'
- Older: 'Azenosertib also has broad franchise potential beyond Cyclin E1-positive PROC' changed to newer: 'We also believe that azenosertib has broad franchise potential beyond Cyclin E1-positive PROC'
- Older: 'Cyclin E1 Protein Expression as a Sensitive and Specific Predictive Biomarker' changed to newer: 'Cyclin E1 Expression as a Sensitive and Specific Predictive Biomarker in PROC'
- Older: 'Cyclin E1 protein overexpression' changed to newer: 'Cyclin E1 activation' in mechanism discussion
- Older: 'We are working with a diagnostic partner to develop a companion diagnostic test' changed to newer: 'We are working with a diagnostic partner to validate a companion diagnostic test'
- Older: 'A prototype of this test is being used in DENALI Part 2' changed to newer: 'A prototype of this test is being used in DENALI Part 2 and our Phase 3 ASPENOVA clinical trial'
- Older: 'we believe there is a large market opportunity' changed to newer: 'we believe there is a significant opportunity'
- Older: 'the limited overlap between FRα-high PROC patients and those that have Cyclin E1 overexpression is estimated to be less than 20%' changed to newer: adds 'of all PROC patients' at end
- Older: 'pharmacokinetic properties' changed to newer: 'pharmacokinetic, or PK, properties'
- Older: 'Tissue collection for biomarker assessment was mandated in the study and upon a retrospective analysis, approximately 50% of the patients were Cyclin E1-positive per our proprietary IHC cutoff' changed to newer: 'per our IHC cutoff' (removed 'proprietary')
- Notes:
- Older filing text is truncated at end of Clinical Development Program section, making full comparison of Phase 3 trial description and USC trial section incomplete
- Newer filing text is also truncated mid-sentence in ASPENOVA description, limiting complete comparison of Phase 3 clinical trial details
Risk Factors
- Added:
- In newer filing (2026-05-12): Net loss figures updated to "$137.1 million for the year ended December 31, 2025" and "$35.4 million and $48.3 million for the three months ended March 31, 2026 and March 31, 2025, respectively"
- In newer filing (2026-05-12): Accumulated deficit figure updated to "$1.2 billion" as of March 31, 2026
- Removed:
- In older filing (2025-11-10): "and interest rates" phrase removed from economic issues discussion
- In older filing (2025-11-10): Net loss figures "$165.9 million for the year ended December 31, 2024" and "$101.8 million and $118.4 million for the nine months ended September 30, 2025 and September 30, 2024, respectively" replaced with new figures
- Reworded:
- Updated period references from "nine months ended September 30" (older filing) to "three months ended March 31" (newer filing)
- Changed "and interest rates" to removal of that phrase from the list of economic issues in economic disruption discussion (newer filing removed reference to interest rates)
- Notes:
- Both filings are truncated at the end of the Risk Factors section; comparison is limited to the complete portions available
- Numerical changes reflect updated financial results for different reporting periods rather than restatements of prior periods
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
1 open-market purchase and 0 open-market sales by insiders in the last 90 days.
- Last 30 days1 buy ($15M) · 0 sells — 1 buying insider
- Last 90 days1 buy ($15M) · 0 sells — 1 buying insider
- Last 180 days1 buy ($15M) · 0 sells — 1 buying insider
Activity heuristic: net buying (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-14. As of 2026-08-25.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about ZNTL's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding ZNTL as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 5,497,872
- Reported value $12,865,021
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 2 increased, 3 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
ZNTL had 5,578,646 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
ZNTL had 7.78% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 4.16 days to cover at the same settlement.
- Reported short interest (shares) 5,578,646
- Short interest (% of shares outstanding) 7.78%
- Prior settlement (shares) 6,146,782
- Reported change -9.24%
- Days to cover (reported) 4.16
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare ZNTL vs…
Frequently asked questions
What does ZENTALIS PHARMACEUTICALS INC (ZNTL) do?
Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of small molecule therapeutics for oncology. Its lead candidate, azenosertib (ZN-c3), is an investigational WEE1 inhibitor designed to treat patients with Cyclin E1-positive platinum-resistant ovarian cancer (PROC) and other solid tumor types.
What sector is ZENTALIS PHARMACEUTICALS INC (ZNTL) in?
ZENTALIS PHARMACEUTICALS INC (ZNTL) is classified in the Health Care sector. Its industry is Clinical-stage oncology / biopharmaceuticals; WEE1 kinase inhibitors. It trades on NASDAQ.
Who are ZENTALIS PHARMACEUTICALS INC's (ZNTL) competitors?
Notable peers of ZENTALIS PHARMACEUTICALS INC (ZNTL) include AstraZeneca, Merck, AbbVie, Bristol Myers Squibb and Pfizer. This peer set is informational only — not financial advice.
Is ZENTALIS PHARMACEUTICALS INC (ZNTL) overbought or oversold right now?
ZENTALIS PHARMACEUTICALS INC (ZNTL) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 41, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on ZNTL come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.